Literature DB >> 7942794

Pulmonary hypertension in polycythemia vera.

S Nand1, E Orfei.   

Abstract

Thromboembolic events occur in about 27% of the patients with polycythemia vera and account for 31% of the deaths. These include cerebrovascular accidents, myocardial infarction, peripheral vascular occlusions, pulmonary infarctions, and venous thrombosis. We report two cases with polycythemia vera who presented with pulmonary hypertension in the absence of previous thromboembolic complications of any kind. One patient died suddenly, with evidence of extensive bilateral thrombosis of prelobular pulmonary arteries at autopsy. In the second patient, local thrombosis in the pulmonary vasculature or recurrent silent pulmonary emboli appear to be responsible for the development of pulmonary hypertension. After institution of anticoagulant therapy, he is able to maintain his functional status. The purpose of this report is to alert clinicians to the development of this insidious, but potentially fatal complication in patients with polycythemia vera.

Entities:  

Mesh:

Year:  1994        PMID: 7942794     DOI: 10.1002/ajh.2830470320

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  10 in total

1.  Association of Hemoglobin and Blood Pressure in a Chinese Community-Dwelling Population.

Authors:  Yan Xuan; Junli Zuo; Shuping Zheng; Jinbao Ji; Yi Qian
Journal:  Pulse (Basel)       Date:  2018-11-28

2.  Cardiovascular Manifestations of Myeloproliferative Disorders: A Review of the Literature.

Authors:  Muhammad Wasif Saif; Umer Khan; Bernard R Greenberg
Journal:  Hosp Physician       Date:  1999-07

3.  Cardiac Complications of Myeloproliferative Disorders.

Authors:  Muhammad Wasif Saif; Umer Khan; Bernard R Greenberg
Journal:  Resid Staff Physician       Date:  2001-07

Review 4.  Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.

Authors:  Roberto F Machado; Harrison W Farber
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

Review 5.  Pulmonary arterial hypertension.

Authors:  David Montani; Sven Günther; Peter Dorfmüller; Frédéric Perros; Barbara Girerd; Gilles Garcia; Xavier Jaïs; Laurent Savale; Elise Artaud-Macari; Laura C Price; Marc Humbert; Gérald Simonneau; Olivier Sitbon
Journal:  Orphanet J Rare Dis       Date:  2013-07-06       Impact factor: 4.123

6.  Relationships of Serum Iron Parameters and Hemoglobin with Forced Expiratory Volume in 1 Second in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Mi-Hye Kim; Yong-Hwan Kim; Duk-Chul Lee
Journal:  Korean J Fam Med       Date:  2018-03-22

7.  Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients.

Authors:  Myeong-Won Lee; Hyewon Ryu; Yoon-Seok Choi; Ik-Chan Song; Hyo-Jin Lee; Hwan-Jung Yun; Byung Joo Sun; Jin-Ok Jeong; Deog-Yeon Jo
Journal:  Blood Res       Date:  2020-06-30

8.  Chronic mountain sickness in Chinese Han males who migrated to the Qinghai-Tibetan plateau: application and evaluation of diagnostic criteria for chronic mountain sickness.

Authors:  Chunhua Jiang; Jian Chen; Fuyu Liu; Yongjun Luo; Gang Xu; Hai-Ying Shen; Yuqi Gao; Wenxiang Gao
Journal:  BMC Public Health       Date:  2014-07-09       Impact factor: 3.295

9.  Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension-A Genetic Study.

Authors:  Christina A Eichstaedt; Jeremias Verweyen; Michael Halank; Nicola Benjamin; Christine Fischer; Eckhard Mayer; Stefan Guth; Christoph B Wiedenroth; Benjamin Egenlauf; Satenik Harutyunova; Panagiota Xanthouli; Alberto M Marra; Heinrike Wilkens; Ralf Ewert; Katrin Hinderhofer; Ekkehard Grünig
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

10.  Hemoglobin and hematocrit levels are positively associated with blood pressure in children and adolescents 10 to 18 years old.

Authors:  Hwal Rim Jeong; Young Suk Shim; Hae Sang Lee; Jin Soon Hwang
Journal:  Sci Rep       Date:  2021-09-24       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.